首页> 外文期刊>Cancer Biomarkers >Detection of lung cancer in silicosis patients using a tumor-marker panel
【24h】

Detection of lung cancer in silicosis patients using a tumor-marker panel

机译:使用肿瘤标志物检测矽肺病患者的肺癌

获取原文
获取原文并翻译 | 示例
           

摘要

Background: This study evaluates the diagnostic power of a fuzzy classifier and a tumor marker panel for the detection of lung cancers in comparison to pneumoconiosis patients at high-risk of developing lung cancer.Methods: CEA, CYFRA 21-1, NSE, SCC and CRP were measured in newly diagnosed lung cancer patients of different histological types and stages in comparison to patients suffering from silicosis. First a fuzzy classifier was generated with a set of 216 primary lung cancer patients (158 non-small cell lung cancer (NSCLC) and 58 small cell lung cancer (SCLC) patients) and 127 patients suffering from pneumoconiosis (51 silicosis and 76 asbestosis). Subsequently, the classifier was validated on a second cohort of 38 NSCLC patients, 55 silicosis patients, 32 patients with chronic obstructive airway diseases (COLD) and 28 healthy control subjects. Results: At 95%-specificity, NSCLC patients were detected in 50% at stage I (n= 30), in 64% at stage II (n=22), in 82% at stage III (n=56), in 88% at stage IV (n=50) and SCLC patients with limited disease status (n=21) in 71% and with extensive disease status (n=37) in 89% by use of the fuzzy classifier. Detection rates of single markers were below those. For the best single marker in NSCLC, CYFRA 21-1, sensitivities were 23.3% at stage I, 45.4% at stage II, 71.4% at stage III, 84% at stage IV (n=50), respectively. For the best single marker in SCLC, NSE, sensitivities were 61.9% at stage of limited disease and 81.1% at stage of extensive disease. In the validation set, the fuzzy classifier showed correct negative classification in 49 of the 55 cancer-free silicosis patients (specificity: 89%), in all COLD patients (specificity: 100%) and in all but one healthy subject (specificity: 96%). This confirmed an overall specificity of 93.9%. The sensitivity for lung cancer detection in high risk populations was 73.6%. All large cell carcinomas could be detected. The positive predictive value was 80%. The negative predictive value reached 91.5%.Conclusion: With the fuzzy classifier and a marker panel a reliable diagnostic tool for the detection of lung cancers in a high risk population is available.
机译:背景:本研究评估了与患有高发肺癌的尘肺病患者相比,模糊分类器和肿瘤标记物组对肺癌检测的诊断能力。方法:CEA,CYFRA 21-1,NSE,SCC和与患有矽肺病的患者相比,在不同组织学类型和阶段的新诊断肺癌患者中测量了CRP。首先,对一组216名原发性肺癌患者(158个非小细胞肺癌(NSCLC)和58个小细胞肺癌(SCLC)患者)和127名患有尘肺病(51个矽肺病和76个石棉沉着病)的患者进行了模糊分类。 。随后,该分类器在第二队列38例NSCLC患者,55例矽肺患者,32例慢性阻塞性气道疾病(COLD)和28例健康对照者中得到了验证。结果:在95%的特异性下,NSCLC患者在第一阶段(n = 30)中检出率为50%,在第二阶段(n = 22)中检出率为64%,在第三阶段(n = 56)中检出率为82%,在88例中检出使用模糊分类器,IV期(n = 50)和SCLC患者的疾病状态受限(n = 21)占71%,广泛疾病状态(n = 37)占89%的SCLC患者的百分比为89%。单个标记的检出率低于那些。对于NSCLC中最好的单一标记物CYFRA 21-1,在第一阶段的敏感性分别为23.3%,在第二阶段的敏感性为45.4%,在第三阶段的敏感性为71.4%,在第四阶段的敏感性为84%(n = 50)。对于SCLC,NSE中最好的单一标记物,在有限疾病阶段的敏感性为61.9%,在广泛疾病阶段的敏感性为81.1%。在验证集中,模糊分类器在55名无癌症的矽肺病患者中的49名(特异性:89%),所有COLD患者(特异性:100%)以及除一名健康受试者外,所有其他患者(特异性:96%)均显示正确的阴性分类。 %)。这证实了93.9%的整体特异性。高危人群中检测肺癌的敏感性为73.6%。可以检测到所有大细胞癌。阳性预测值为80%。阴性预测值达到91.5%。结论:有了模糊分类器和标记面板,可以使用一种可靠的诊断工具来检测高危人群中的肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号